Takeda (TAK) President IBU sells 31,083 ADSs in tax-related transaction

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD executive Giles Richard Platford, President, IBU, reported a sale of 31,083 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes tied to the vesting of equity awards, and his direct holdings after the transaction were 315,838 ADSs. The transaction was reported as a sale in the open market or a private transaction and was not marked as executed under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 31,083 shares

Net Sell 1 txn

Insider Platford Giles Richard

Role President, IBU

Sold 31,083 shs ($532K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	31,083	$17.10	$532K

Holdings After Transaction: American Depositary Shares — 315,838 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 31,083 ADSs Weighted average sale price: $17.10 per ADS Holdings after transaction: 315,838 ADSs

3 metrics

Shares sold 31,083 ADSs Non-derivative sale on 2026-08-10 to cover taxes

Weighted average sale price $17.10 per ADS Price for 31,083 ADSs sold on 2026-08-10

Holdings after transaction 315,838 ADSs Direct ownership following the 31,083-share sale

Key Terms

American Depositary Shares, weighted average price, mandatory sale to cover taxes, equity awards

4 terms

American Depositary Shares financial

"security_title: American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

equity awards financial

"taxes associated with the vesting of equity awards held by the Reporting Person"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

FAQ

What insider transaction did TAK (Takeda Pharmaceutical) report for Giles Richard Platford?

Takeda reported that Giles Richard Platford sold 31,083 American Depositary Shares on 2026-08-10. The sale was disclosed as a transaction in ADSs and categorized as a non-derivative security sale.

At what price were the 31,083 Takeda (TAK) ADSs sold by Giles Richard Platford?

The 31,083 Takeda American Depositary Shares were sold at a weighted average price of $17.10 per share. The insider undertook to provide detailed breakdowns of the individual prices upon request to relevant parties.

Why did Giles Richard Platford sell 31,083 Takeda (TAK) ADSs?

The disclosure states the sale of 31,083 ADSs was a mandatory sale to cover taxes related to the vesting of equity awards. This indicates the transaction was executed for tax obligations on those vested awards.

How many Takeda (TAK) ADSs does Giles Richard Platford hold after this sale?

After the reported sale, Giles Richard Platford held 315,838 American Depositary Shares directly. This figure reflects his direct ownership position immediately following the 31,083-share transaction on 2026-08-10.

Was the Takeda (TAK) insider sale by Giles Richard Platford under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction. This indicates the 31,083-share sale was not affirmatively reported as executed under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 09:26 PM Accepted by SEC EDGAR 08/12/2026 - 09:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Platford Giles Richard

(Last) (First) (Middle)

650 E. KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, IBU

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		31,083	D	$17.1(2)	315,838	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Giles R. Platford	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)